ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Agilex Biolabs, the Australian regulated bioanalytical and toxicology laboratory facilities for clinical trials is presenting a new webinar entitled “Getting it right! Considerations for Immuno-oncology and Vaccine Studies and the Bioanalytical Tools used” in partnership with Outsourcing Clinical Trials (OCT).
Agilex Biolabs’ Director, Immunoassay, Kurt J. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D, PGCM) said:
“Choosing the right bioanalytical platform for your immunology or vaccines clinical trial is critical to data collection. But navigating the intricate bioanalytical process and selection of assay platforms can be difficult. This webinar covers these platforms in detail and the selection process.”
Agilex Biolabs is the largest regulated bioanalytical laboratory in Australia with over 24 years’ experience in early phase clinical trials with a track record of enabling the movement of new drug entities to market.
Agilex Biolabs specialises in pharmacokinetics, pharmacodynamics, and biomarker evaluation, which is key to understanding the drug absorption, distribution, metabolism, and excretion as well as target engagement and efficacy of the drug during clinical development.
“This webinar will demystify the bioanalytical requirements for clinical studies and will discuss the most common bioanalytical platforms used during clinical trials to measure vaccine responses and levels of inflammatory mediators in biological fluids,” said Dr. Sales.
Key Learning Objectives
– Learn how to determine the right bioanalytical platform for your immunology or vaccines clinical trial
– Understand what do these bioanalytical platforms look like in use
– Understand the process of selecting the right bioanalytical platform
– Demystify the bioanalytical requirements for clinical studies
The webinar will also cover Australian research, and regulatory and clinical infrastructure, which provides a favorable environment for rapid vaccine development. It will also include discussion of a case study for rapid vaccine development based on non-clinical research conducted with a novel COVID-19 protein subunit vaccine.
Register Here https://bit.ly/3aPlWsx
Date: 4 November
Time: 2PM London/3PM CET
Speaker: Dr Kurt Sales: Director, Immunoassay, Agilex Biolabs
Agilex Biolabs’ world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and digital droplet quantitative real-time RT-PCR.
The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.
Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.
Agilex Biolabs has more than 140 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.
Book a confidential briefing with our scientists before you start your next clinical trial. https://calendly.com/agilexbiolabs/30min
